“Ardelyx Gets Strong Buy Nod from Raymond James Amid Drug Price Hike”
Raymond James reiterates a Strong Buy rating for the biopharmaceutical company, Ardelyx, maintaining a $16 price target. Encouraging trends in the increased usage of Ardelyx's key products Xphozah and Ibsrela, and recent price hikes, have prompted Raymond James' positive review. Read more
Read More“Ardelyx Gets Raymond James’ Strong Buy Rating After Drug Price Hike”
Raymond James reasserts its Strong Buy rating for biopharmaceutical company Ardelyx, amidst price increases for essential products, Xphozah and Ibsrela. This optimism reflects the growing consumer utilization trend, promising future growth, and a potential boost in Ardelyx's overall financial performance. Read more
Read More
“Aletheia Upgrades ASML Stock to Buy, Shares Skyrocket”
Shares of semiconductor equipment giant ASML soar after a double upgrade from Aletheia Capital. Driven by an optimistic long-term outlook on the semiconductor industry and surging demand for advanced chip designs, ASML's growth potential is underscored. With a unique market position, ASML is poised to benefit from the ongoing digital transformation. Read more
Read More